Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.
Approaches to slow or reverse aging have gained momentum in recent years, but the field is still in its infancy with hurdles to overcome, as illustrated by efforts to develop therapies that clear senescent cells.
High-value cell therapy deals are driving investment in the cell and gene therapy field, but new approaches such as gene editing are also beginning to contribute.
Companies that have pioneered platforms based on oligonucleotides targeting RNA and their biopharma partners continue to move beyond rare diseases into broader patient populations with cardiovascular diseases and central nervous system disorders.
While external factors have put a dampener on acquisitions of oncology companies in the past year, the search for next-generation therapeutics from innovative platforms has driven dealmaking.
The development of antibodies and associated technologies continues to drive high-value deals. We look at recent trends in the field with help from DealForma.
The promise of accessing tissues beyond the liver is driving deals between pioneers in the field of nucleic-acid-based drugs and companies developing delivery platforms.
The potential of companies developing artificial intelligence (AI)-based tools for drug discovery and development has driven investment and deals with major biopharma companies, but challenges for AI biotechs and biopharma companies are emerging as the field moves beyond the hype towards impact.
